

Application No. 10/801,050 ----- 2

Remarks

Claims 1-20 and 30-40 are pending in this application.

Claims 21-29 have been cancelled.

Claims 5-7, 18, 19, and 36 have been withdrawn.

In response to the requirement for restriction, Applicants elect for prosecution at this time the claims of Group I, i.e., claims 1-20 and 30-40 drawn to methods of treating or preventing a myocardial infarction. This election is made without traverse.

Regarding the election of species, applicants elect for further prosecution at this time the method that utilizes, as the active ingredient 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile (SKI-606).

This species election is made without traverse. The elected method species is defined by claim 12. Claims 1-4, 8-17, 20, 30-35 and 37-40 read on the elected species.

An early action on the merits is solicited.

Respectfully submitted,

September 14, 2007

By 
Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this RESPONSE TO RESTRICTION REQUIREMENT is being transmitted by facsimile transmission to Fax No. 571-273-8300 on September 14, 2007.


Talivaldis Cepuritis (Reg. No. 20,818)